MCID: NRT001
MIFTS: 57

Neurotic Disorder

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Neurotic Disorder

MalaCards integrated aliases for Neurotic Disorder:

Name: Neurotic Disorder 11 14 16 75
Neurosis 11 14 75
Adjustment Disorders 43 71
Reactive Depression 11 71
Neurotic Disorders 43 71
Neurotic Depression Reactive Type 11
Neurotic Depressive State 11
Depression, Neurotic 71
Depressive Neurosis 11
Neurotic Depression 11
Depressive Disorder 71
Psychoneurosis 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4964
UMLS 71 C0001546 C0011579 C0011581 more

Summaries for Neurotic Disorder

Disease Ontology: 11 An anxiety disorder that involves discress but neither delusions nor hallucinations.

MalaCards based summary: Neurotic Disorder, also known as neurosis, is related to conversion disorder and obsessive-compulsive personality disorder, and has symptoms including depressed reaction and depressed - symptom. An important gene associated with Neurotic Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Signal Transduction and NF-KappaB Family Pathway. The drugs Valsartan and Suvorexant have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and temporal lobe, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 Neurosis is a class of functional mental disorders involving chronic distress, but neither delusions nor... more...

Related Diseases for Neurotic Disorder

Diseases related to Neurotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
# Related Disease Score Top Affiliating Genes
1 conversion disorder 32.0 HTR2A COMT BDNF
2 obsessive-compulsive personality disorder 30.3 SLC6A4 HTR2A COMT
3 graves disease 1 30.3 POMC INS CRP
4 obsessive-compulsive disorder 30.3 TNF SLC6A4 POMC OXT MAOA IL6
5 trichotillomania 30.3 SLC6A4 MAOA BDNF
6 duodenal ulcer 30.2 TNF INS IL6 IL1B
7 body dysmorphic disorder 30.2 SLC6A4 OXT MAOA HTR2A
8 factitious disorder 30.1 POMC INS
9 antisocial personality disorder 30.1 SLC6A4 OXT MAOA HTR2A COMT
10 dissociative disorder 30.1 SLC6A4 OXT HTR2A COMT BDNF
11 diabetes insipidus 30.1 POMC OXT INS CRH
12 inflammatory bowel disease 1 30.1 TNF IL6 IL1B
13 premenstrual tension 30.0 POMC LIPN
14 rheumatic heart disease 30.0 TNF IL6 IL1B
15 amnestic disorder 30.0 OXT NGF HTR1A BDNF
16 tic disorder 29.9 SLC6A4 MAOA HTR2A HTR1A COMT
17 hyperthyroidism 29.9 TNF POMC INS IL6 CRP
18 peptic esophagitis 29.9 TNF IL6 IL1B
19 esophagitis 29.9 TNF IL6 IL1B
20 angina pectoris 29.9 TNF INS IL6 CRP
21 headache 29.8 TNF SLC6A4 HTR2A COMT BDNF
22 sheehan syndrome 29.8 POMC INS CRH
23 personality disorder 29.8 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
24 arachnoiditis 29.8 TNF POMC IL1B CRP
25 delusional disorder 29.7 HTR2C HTR2A HTR1A COMT
26 cyclothymic disorder 29.7 SLC6A4 HTR2A HTR1A COMT BDNF
27 hypoglycemia 29.7 POMC OXT INS CRH BDNF
28 hyperprolactinemia 29.7 POMC INS HTR2C HTR2A
29 pharyngitis 29.7 TNF IL6 IL1B CRP
30 vascular dementia 29.6 TNF INS IL6 IL1B HTR1A BDNF
31 brucellosis 29.6 TNF IL6 CRP
32 opiate dependence 29.6 SLC6A4 POMC CRH COMT BDNF
33 nutritional deficiency disease 29.6 IL6 CRP BDNF
34 spondyloarthropathy 29.6 TNF IL6 IL1B CRP
35 somatization disorder 29.6 SLC6A4 POMC PCSK5 OXT IL6 CRH
36 withdrawal disorder 29.6 SLC6A4 POMC HTR1A CRH BDNF
37 diarrhea 29.6 TNF SLC6A4 IL6 IL1B HTR1A BDNF
38 peptic ulcer disease 29.6 TNF INS IL6 IL1B CRP
39 conduct disorder 29.5 SLC6A4 POMC OXT MAOA COMT
40 acute stress disorder 29.5 SLC6A4 POMC OXT HTR2A CRH BDNF
41 schizoaffective disorder 29.5 SLC6A4 INS HTR2A HTR1A COMT BDNF
42 dermatitis, atopic 29.5 TNF NGF IL6 IL1B BDNF
43 restless legs syndrome 29.4 SLC6A4 POMC MAOA IL1B COMT
44 pneumonia 29.4 TNF IL6 IL1B CRP
45 paranoid schizophrenia 29.4 SLC6A4 MAOA HTR2C HTR2A HTR1A COMT
46 scarlet fever 29.4 TNF IL6 IL1B CRP
47 pulmonary tuberculosis 29.4 TNF IL6 IL1B CRP
48 sexual health disorder 29.4 SLC6A4 OXT MAOA HTR2C HTR2A HTR1A
49 gout 29.4 TNF INS IL6 IL1B CRP
50 common cold 29.4 TNF IL6 IL1B CRP

Graphical network of the top 20 diseases related to Neurotic Disorder:



Diseases related to Neurotic Disorder

Symptoms & Phenotypes for Neurotic Disorder

UMLS symptoms related to Neurotic Disorder:


depressed reaction; depressed - symptom

MGI Mouse Phenotypes related to Neurotic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.31 BDNF COMT CRH HTR1A HTR2C IL1B
2 homeostasis/metabolism MP:0005376 10.3 BDNF COMT CRH CRP HTR1A HTR2C
3 no phenotypic analysis MP:0003012 10.06 BDNF CRH HTR1A INS NGF PCSK5
4 endocrine/exocrine gland MP:0005379 10.06 BDNF COMT CRH HTR2A IL6 INS
5 cardiovascular system MP:0005385 9.97 COMT CRP HTR1A IL1B IL6 INS
6 adipose tissue MP:0005375 9.95 CRH HTR2C IL6 INS OXT POMC
7 digestive/alimentary MP:0005381 9.86 BDNF HTR2A IL6 INS OXT PCSK5
8 behavior/neurological MP:0005386 9.83 BDNF COMT CRH HTR1A HTR2A HTR2C
9 integument MP:0010771 9.36 BDNF CRH HTR2C IL1B IL6 INS

Drugs & Therapeutics for Neurotic Disorder

Drugs for Neurotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 625)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
3
Oxcarbazepine Approved Phase 4 28721-07-5 34312
4
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
5
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
8
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
9
Doxepin Approved, Investigational Phase 4 1668-19-5 667468 667477
10
Isocarboxazid Approved Phase 4 59-63-2 3759
11
Protriptyline Approved Phase 4 438-60-8 4976
12
Trimipramine Approved Phase 4 739-71-9 5584
13
Tranylcypromine Approved, Investigational Phase 4 155-09-9 5530 441233
14
Ziprasidone Approved Phase 4 146939-27-7 60854
15
Desipramine Approved, Investigational Phase 4 50-47-5 2995
16
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
17
Maprotiline Approved, Investigational Phase 4 10262-69-8 4011
18
Topiramate Approved Phase 4 97240-79-4 5284627
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Simvastatin Approved Phase 4 79902-63-9 54454
21
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
22
Ribavirin Approved Phase 4 36791-04-5 37542
23
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
24
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
25
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
26
Calcium carbonate Approved, Investigational Phase 4 471-34-1
27
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Nefazodone Approved, Withdrawn Phase 4 82752-99-6, 83366-66-9 4449
30
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
31
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
32
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
33
Acamprosate Approved, Investigational Phase 4 77337-73-6, 77337-76-9 71158
34
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
35
Metamfetamine Approved, Illicit, Withdrawn Phase 4 537-46-2 10836
36
Iloperidone Approved Phase 4 133454-47-4 71360
37
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
38
Losartan Approved Phase 4 114798-26-4 3961
39
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
40
Zolpidem Approved Phase 4 82626-48-0 5732
41
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
42
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
43
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
44
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
45
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
46
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
47
Donepezil Approved Phase 4 120014-06-4 3152
48
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
49
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
50
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934

Interventional clinical trials:

(show top 50) (show all 4825)
# Name Status NCT ID Phase Drugs
1 Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder Unknown status NCT02752542 Phase 4 Pharmacotherapy
2 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
3 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
4 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
5 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
6 Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR) Unknown status NCT02711215 Phase 4 Citalopram;Escitalopram (Mirtazapine/Duloxetine/Venlafaxine);Placebo
7 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
8 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
9 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
10 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
11 Ketamine Enhancement of rTMS for Refractory Depression Unknown status NCT04352621 Phase 4 intranasal ketamine
12 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
13 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
14 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
15 A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder Unknown status NCT04138290 Phase 4
16 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
17 Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy Unknown status NCT03187093 Phase 4 Vortioxetine;Escitalopram
18 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
19 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Unknown status NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
20 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
21 Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial Unknown status NCT03666494 Phase 4 Ketamine Hydrochloride;Propofol;Fentanyl
22 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
23 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
24 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
25 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
26 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
27 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
28 Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
29 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
30 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Bupropion;Trazodone
31 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
32 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
33 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
34 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
35 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
36 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
37 A Prospective, Single-Blinded, Randomized, Multicentre Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Subjects With a Primary Diagnosis of a Depressive Disorder Unknown status NCT04620499 Phase 4
38 Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT04589143 Phase 4 Agomelatine;Placebos
39 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
40 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
41 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
42 Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression Unknown status NCT04234776 Phase 4 Ketamine
43 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
44 Objective to Evaluate the Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Depressive Episode: a Multicenter Open Randomized Controlled Clinical Trial Unknown status NCT04826510 Phase 4 Perospirone hydrochloride tablets;Lithium carbonate + perospirone hydrochloride;Lithium Carbonate Pill
45 Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Unknown status NCT03491696 Phase 4 Metyrapone
46 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
47 The Assessment of Osteoporosis Treatment in Post-menopausal Women Unknown status NCT03006003 Phase 4 Raloxifene;Alendronate
48 Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression Unknown status NCT03328052 Phase 4
49 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
50 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4

Search NIH Clinical Center for Neurotic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: adjustment disorders

Genetic Tests for Neurotic Disorder

Anatomical Context for Neurotic Disorder

Organs/tissues related to Neurotic Disorder:

MalaCards : Brain, Prefrontal Cortex, Temporal Lobe, Cortex, Heart, Pituitary, Bone Marrow

Publications for Neurotic Disorder

Articles related to Neurotic Disorder:

(show top 50) (show all 5596)
# Title Authors PMID Year
1
Traditional uses, chemical compounds, pharmacological activities and clinical studies on the traditional Chinese prescription Yi-Gan San. 62
36280017 2023
2
Anatomical Variations of the Axillary Arch and Implications in Breast Surgery. 62
36179595 2023
3
Efficacy of computer- and/or internet-based cognitive-behavioral guided self-management for depression in adults: a systematic review and meta-analysis of randomized controlled trials. 62
36424570 2022
4
The phylogenetic argument in Freud's metapsychology of anxiety. 62
36200360 2022
5
The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis. 62
36205586 2022
6
Study on the active components and mechanism of Suanzaoren decoction in improving cognitive impairment caused by sleep deprivation. 62
35777606 2022
7
A quarter of century after: The changing ecology of psychiatric emergency services. 62
34510765 2022
8
Distinguishing between neurosis and psychosis: discourses on neurosis in colonial Korea. 62
35979864 2022
9
Do Limited English Proficiency and Language Moderate the Relationship Between Mental Health and Pain? 62
34824021 2022
10
The efficacy and optimal matching of an Internet-based acceptance and commitment therapy intervention for depressive symptoms among university students: A randomized controlled trial in China. 62
35191525 2022
11
Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study. 62
35462611 2022
12
Relationships between treatments received in the Nottingham Study of Neurotic Disorder over 30 years and personality status. 62
34981662 2022
13
New data toward fulfilling the promise of the ICD-11 severity criterion. 62
35581693 2022
14
The recording of personality strengths: An analysis of the impact of positive personality features on the long-term outcome of common mental disorders. 62
35532104 2022
15
Stimulant use in patients presenting with psychocutaneous disorders. 62
33878406 2022
16
Personality change in the Nottingham Study of Neurotic Disorder: 30-Year cohort study. 62
34250845 2022
17
Glucagon Response to Glucose Challenge in Patients with Idiopathic Postprandial Syndrome. 62
34526455 2022
18
Effectiveness and safety of kamikihito, a traditional Japanese medicine, in managing anxiety among female patients with intractable chronic constipation. 62
34974326 2022
19
Neurotherapy of Yi-Gan-San, a Traditional Herbal Medicine, in an Alzheimer's Disease Model of Drosophila melanogaster by Alleviating Aβ42 Expression. 62
35214904 2022
20
Chronic widespread pain in children and adolescents presenting in primary care: prevalence and associated risk factors. 62
34108433 2022
21
Diseases prevalent before major depressive disorder diagnosis: an exploratory nested case-control study using health insurance-based claims data. 62
35168961 2022
22
[Clinical features of schizotypal disorder in childhood and adolescence]. 62
36170092 2022
23
[Assessment of the initial period of schizotypal disorder in childhood]. 62
35758955 2022
24
Voiding and storage symptoms in depression/anxiety. 62
34923228 2022
25
Carpal tunnel syndrome in children: a case report. 62
35465368 2022
26
[Neurocognitive functioning in young patients with chronic endogenous depression]. 62
35797192 2022
27
Serum NLRP3 Inflammasome and BDNF: Potential Biomarkers Differentiating Reactive and Endogenous Depression. 62
35295780 2022
28
Yokukansan Inhibits the Development of Morphine Tolerance by Regulating Presynaptic Proteins in DRG Neurons. 62
35662731 2022
29
Anna Livia Plurabelle's normless interactions in Finnegans Wake. 62
36275223 2022
30
[Concepts of nymphomania in the German academic psychiatry: Changes over the last two centuries]. 62
33592669 2022
31
Association between psychological resilience and cognitive function in older adults: effect modification by inflammatory status. 62
34184172 2021
32
Rhaponticum uniflorum and Serratula centauroides Extracts Attenuate Emotional Injury in Acute and Chronic Emotional Stress. 62
34832968 2021
33
Kihito prevents corticosterone-induced brain dysfunctions in mice. 62
34765515 2021
34
Liquid-Liquid Chromatography Separation of Guaiane-Type Sesquiterpene Lactones from Ferula penninervis Regel & Schmalh. and Evaluation of Their In Vitro Cytotoxic and Melanin Inhibitory Potential. 62
34639057 2021
35
Bernard Hart (1879-1966) and his influence on British psychiatry. 62
34636681 2021
36
Efficacy of Yokukansan, a traditional Japanese herbal medicine, in patients with dizziness and irritability. 62
33526322 2021
37
Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: A Health Insurance Claims Database Analysis. 62
34263331 2021
38
The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. 62
34505377 2021
39
Blasphemous thoughts in obsessive-compulsive disorder: A case series. 62
34908704 2021
40
Bipolar Depression: A Historical Perspective of the Current Concept, with a Focus on Future Research. 62
34310532 2021
41
Psychological nursing intervention improve the mental health status of young patients with lung cancer surgery during the perioperative period. 62
34397814 2021
42
Prenatal and Postnatal Anxiety and Depression in Mothers during the COVID-19 Pandemic. 62
34300358 2021
43
Diving-related disorders in commercial breath-hold divers (Ama) of Japan. 62
34157736 2021
44
Hepatic encephalopathy induced by Lenvatinib and anti-PD-1 mAb in a patient with advanced hepatocellular carcinoma: A case report. 62
33859824 2021
45
Obsessive-Compulsive Disorders and Functional Urinary Disorders: A Fortuitous Association? 62
34204468 2021
46
Neuropsychopharmacology and the Forgotten Language of Psychiatry Madness: From Psychiatry to Neuronology via Neuropsychopharmacology. 62
34342417 2021
47
Synthesis and Neurotropic Activity of New Heterocyclic Systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, Pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and Pyridofuro[3',2':4,5]pyrimido[1,2-a]azepines. 62
34205930 2021
48
Correlates of psychological resilience and risk: Prospective associations of self-reported and relative resilience with Connor-Davidson resilience scale, heart rate variability, and mental health indices. 62
33638932 2021
49
Plica neuropathica in severe reactive depression: clinical and trichoscopic features. 62
34118824 2021
50
Short-term Changes in Self-rating Depression Scale Scores after Smoking Cessation in Neurotic Patients. 62
33055476 2021

Variations for Neurotic Disorder

Expression for Neurotic Disorder

Search GEO for disease gene expression data for Neurotic Disorder.

Pathways for Neurotic Disorder

Pathways related to Neurotic Disorder according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1 13.56 BDNF CRH HTR1A HTR2A HTR2C IL6
2
Show member pathways
12.64 TNF NGF IL6 IL1B BDNF
3 12.63 NGF INS IL6 IL1B BDNF
4
Show member pathways
12.58 TNF NGF IL6 IL1B BDNF
5 12.36 TNF NGF IL1B BDNF
6 12 TNF NGF IL6 IL1B BDNF
7 11.9 TNF IL6 IL1B BDNF
8 11.84 TNF POMC MAOA IL6 IL1B
9 11.71 TNF IL6 IL1B
10 11.7 TNF IL6 IL1B
11 11.68 TNF IL6 CRP
12
Show member pathways
11.62 TNF IL6 IL1B
13 11.61 TNF IL6 IL1B
14 11.6 IL1B IL6 TNF
15 11.54 NGF IL6 BDNF
16 11.48 TNF SLC6A4 NGF MAOA IL6 IL1B
17 11.45 TNF IL6 IL1B
18 11.43 TNF INS IL6
19 11.41 TNF IL6 IL1B
20
Show member pathways
11.37 TNF SLC6A4 MAOA IL1B
21 11.3 TNF IL6 IL1B
22 11.25 TNF IL6 IL1B
23 11.21 TNF IL6 IL1B
24 11.21 POMC OXT NGF INS HTR2C BDNF
25 11.19 IL1B IL6 TNF
26 11.15 TNF IL6 IL1B
27
Show member pathways
11.12 POMC HTR2C HTR2A HTR1A CRH
28
Show member pathways
11.08 SLC6A4 MAOA COMT
29 11 SLC6A4 MAOA HTR2C HTR2A HTR1A
30
Show member pathways
10.98 SLC6A4 MAOA HTR1A COMT
31 10.97 TNF NGF IL6 IL1B BDNF
32 10.97 POMC INS HTR2C
33 10.93 TNF IL6 CRP
34 10.75 IL6 IL1B
35
Show member pathways
10.62 PCSK5 NGF
36 10.49 POMC CRH
37 10.31 MAOA COMT
38
Show member pathways
10.3 TNF IL6

GO Terms for Neurotic Disorder

Cellular components related to Neurotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 10.03 NGF HTR2C HTR2A HTR1A COMT BDNF
2 extracellular space GO:0005615 10 BDNF CRH CRP IL1B IL6 INS
3 extracellular region GO:0005576 9.7 TNF POMC PCSK5 OXT NGF LIPN
4 G protein-coupled serotonin receptor complex GO:0098666 9.46 HTR2C HTR2A

Biological processes related to Neurotic Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.27 CRH HTR1A HTR2A HTR2C PCDHB14
2 positive regulation of gene expression GO:0010628 10.25 TNF SLC6A4 NGF INS IL6 IL1B
3 signal transduction GO:0007165 10.24 BDNF CRH HTR1A HTR2A HTR2C IL1B
4 defense response to Gram-positive bacterium GO:0050830 10.19 TNF IL6 IL1B CRP
5 regulation of insulin secretion GO:0050796 10.1 TNF IL6 IL1B
6 response to activity GO:0014823 10.09 TNF OXT IL6
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.08 TNF NGF IL6 BDNF
8 acute-phase response GO:0006953 10.06 INS IL6 CRP
9 positive regulation of mitotic nuclear division GO:0045840 10.03 TNF INS IL1B
10 positive regulation of chemokine production GO:0032722 10 TNF IL6 IL1B
11 negative regulation of neurogenesis GO:0050768 9.97 IL1B IL6 TNF
12 negative regulation of lipid catabolic process GO:0050995 9.93 IL1B INS TNF
13 sperm ejaculation GO:0042713 9.91 SLC6A4 OXT
14 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.91 HTR2C HTR2A HTR1A
15 positive regulation of glial cell proliferation GO:0060252 9.91 IL1B IL6 TNF
16 positive regulation of fever generation GO:0031622 9.9 IL1B TNF
17 sequestering of triglyceride GO:0030730 9.87 TNF IL1B
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.85 TNF IL1B
19 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.84 HTR2C HTR2A
20 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.83 HTR2C HTR2A
21 positive regulation of neuroinflammatory response GO:0150078 9.8 TNF IL6 IL1B
22 negative regulation of lipid storage GO:0010888 9.73 TNF IL6 CRP
23 vascular endothelial growth factor production GO:0010573 9.63 TNF IL6 IL1B
24 memory GO:0007613 9.32 SLC6A4 OXT NGF HTR2A BDNF
25 behavior GO:0007610 9.13 HTR2C HTR2A HTR1A

Molecular functions related to Neurotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.91 POMC OXT INS CRH
2 signaling receptor binding GO:0005102 9.86 BDNF CRH IL6 NGF POMC TNF
3 G protein-coupled serotonin receptor activity GO:0004993 9.8 HTR2C HTR2A HTR1A
4 nerve growth factor receptor binding GO:0005163 9.71 NGF BDNF
5 Gq/11-coupled serotonin receptor activity GO:0001587 9.46 HTR2C HTR2A
6 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2C HTR2A
7 serotonin binding GO:0051378 9.23 SLC6A4 HTR2C HTR2A HTR1A

Sources for Neurotic Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....